Skip to main content
SpringerLink
Log in

Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer

  • PHASE II STUDIES
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Background Treatment options for patients with metastatic castration-resistance prostate cancer are unsatisfactory. Docetaxel monotherapy offers promising results with a tolerable toxicity profile. However, enhancing the clinical index of Docetaxel-based therapy remains the ultimate goal. Methods We conducted a phase II, open label, multinational prospective trial to evaluate the efficacy of weekly Docetaxel combined with Zoledronic acid and Celecoxib. Eligible patients received 25 mg/m2 Docetaxel weekly for 3 consecutive weeks every 4 weeks, 4 mg Zoledronic acid every 4 weeks, and 200 mg oral Celecoxib twice daily. Enrollment was terminated prematurely upon the publication of reports of cardiac toxicity associated with cyclooxygenase (COX) 2 inhibitors. Results Our study enrolled 22 patients with a median of 4.7 cycles per patient. The median overall survival (OS) was 9.8 months (range 0.7 to 24.1 months) with 36 % and 4.5 % survival rates at 1 and 2 years, respectively. Our patients had a biologic response in 40.1 % of cases and a palliative response in 72.7 %. Among the eight patients with measurable disease, three had partial responses, two had stable disease, and three had progressive disease, leading to a response rate (RR) of 62.5 %. The observed toxicities were mild and limited to grade 3 events. Nine patients had anemia (40.1 %), 5 had sensory neuropathy (22.7 %) and 2 had stomatitis (9.1 %). Conclusion The combination of Docetaxel, Celecoxib, and Zoledronic acid failed to improve OS or to offer an acceptable biologic response. We do not believe that there is compelling evidence to include either Celecoxib or Zoledronic acid in further phase II/III trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Cancer of the Prostate - SEER Stat Fact Sheets [Internet] (2016) Available from: http://seer.cancer.gov/statfacts/html/prost.html

  2. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al. (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol Off J Am Soc Clin Oncol 14(6):1756–1764

    CAS  Google Scholar 

  3. Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC, et al. (2005) Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol 23(15):3343–3351

    Article  CAS  Google Scholar 

  4. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H (2000) Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42(1):73–78

    Article  CAS  PubMed  Google Scholar 

  5. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS (2000) The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of bcl-2. J Biol Chem 275(15):11397–11403

    Article  CAS  PubMed  Google Scholar 

  6. Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC (2000) Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 164(3 Pt 1):820–825

    Article  CAS  PubMed  Google Scholar 

  7. Liu XH, Yao S, Kirschenbaum A, Levine AC (1998) NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 58(19):4245–4249

    CAS  PubMed  Google Scholar 

  8. Mahmud S, Franco E, Aprikian A (2004) Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer 90(1):93–99

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Pruthi RS, Derksen JE, Moore D (2004) A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. BJU Int 93(3):275–278

    Article  CAS  PubMed  Google Scholar 

  10. Pruthi RS, Derksen JE, Moore D, Carson CC, Grigson G, Watkins C, et al. (2006) Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clin Cancer Res 12(7 Pt 1):2172–2177

    Article  CAS  PubMed  Google Scholar 

  11. Kattan JG, Farhat FS, Chahine GY, Nasr FL, Moukadem WT, Younes FC, et al. (2008) Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC). Investig New Drugs 26(1):75–79

    Article  CAS  Google Scholar 

  12. Kattan J, Bachour M, Farhat F, El Seoudi M, Younes F, Ghosn M, Chahine G. Phase II trial of weekly Docetaxel, Zoledronate and Celecoxib for Androgen-Independent Prostate Cancer Patients. Poster at the Prostate Symposium of the American Society of Clinical Oncology ASCO, USA February 2006. (abstract 362)

  13. Fleming TR (1982) One-sample multiple testing procedure for phase II clinical trials. Biometrics 38(1):143–151

    Article  CAS  PubMed  Google Scholar 

  14. Antonarakis ES, Eisenberger MA (2011) Expanding treatment options for metastatic prostate cancer. N Engl J Med 364(21):2055–2058

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502–1512

    Article  CAS  PubMed  Google Scholar 

  16. Antonarakis ES, Eisenberger MA (2013) Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences. J Clin Oncol Off J Am Soc Clin Oncol 31(14):1709–1712

    Article  CAS  Google Scholar 

  17. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet Lond Engl 387(10024):1163–1177

    Article  CAS  Google Scholar 

  18. James ND, Sydes MR, Mason MD, Clarke NW, Anderson J, Dearnaley DP, et al. (2012) Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol 13(5):549–558

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR et al. (2016) Celecoxib with or without zoledronic acid for hormone-naïve prostate cancer: Survival results from STAMPEDE (NCT00268476). Oral abstract session at the American Society of Clinical Oncology ASCO, J Clin Oncol 34, (suppl 2S; abstr 162)

  20. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411–422

    Article  CAS  PubMed  Google Scholar 

  21. Midgley RS, McConkey CC, Johnstone EC, Dunn JA, Smith JL, Grumett SA, et al. (2010) Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. J Clin Oncol Off J Am Soc Clin Oncol 28(30):4575–4580

    Article  CAS  Google Scholar 

  22. Antonarakis ES, Heath EI, Walczak JR, Nelson WG, Fedor H, De Marzo AM, et al. (2009) Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol Off J Am Soc Clin Oncol 27(30):4986–4993

    Article  CAS  Google Scholar 

  23. Saylor PJ, Lee RJ, Smith MR (2011) Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol 29(27):3705–3714

    Article  Google Scholar 

  24. Brunello A, Fontana A, Zafferri V, Panza F, Fiduccia P, Basso U, et al. (2016) Development of an oncological-multidimensional prognostic index (Onco-MPI) for mortality prediction in older cancer patients. J Cancer Res Clin Oncol 142:1069–1077

    Article  PubMed  PubMed Central  Google Scholar 

  25. Dearnaley DP, Mason MD, Parmar MKB, Sanders K, Sydes MR (2009) Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol 10(9):872–876

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Smith MR, Halabi S, Ryan CJ, Hussain A, Vogelzang N, Stadler W, et al. (2014) Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol Off J Am Soc Clin Oncol 32(11):1143–1150

    Article  CAS  Google Scholar 

  27. James ND, Sydes MR, Mason MD, Clarke NW, Dearnaley DP, Spears MR et al. Docetaxel and/or zoledronic acid for hormone naïve prostate cancer: First overall survival results from STAMPEDE (NCT00268476). Oral abstract session at the American Society of Clinical Oncology ASCO, USA 2015. (abstract 5001)

  28. James ND, Pirrie S, Barton D, Brown JE, Billingham L, Collins SI et al. (2013) Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747). Oral abstract session at the American Society of Clinical Oncology ASCO, J Clin Oncol 31, (suppl; abstr LBA5000)

  29. Hainsworth JD (2004) Practical aspects of weekly docetaxel administration schedules. Oncologist 9(5):538–545

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon

    Joseph Kattan, Fadi Farhat, Elie El Rassy, Tarek Assi & Marwan Ghosn

  2. Nuclear Medicine Center, Bayrouni Center, Damascus, Syria

    Marwan Bachour

Authors
  1. Joseph Kattan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marwan Bachour
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fadi Farhat
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elie El Rassy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tarek Assi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marwan Ghosn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elie El Rassy.

Ethics declarations

Conflict of interest

None.

Sponsor

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kattan, J., Bachour, M., Farhat, F. et al. Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer. Invest New Drugs 34, 474–480 (2016). https://doi.org/10.1007/s10637-016-0357-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-016-0357-4

Keywords

Search

Navigation